Genotyping and Antiretroviral Drug Resistance Mutations among HIV Patients in Southern Santa Catarina, Brazil


Citar

Texto integral

Resumo

Introduction:Therapeutic measures have been successful in increasing survival rates and quality of life of HIV/AIDS-infected people. However, some people fail to respond to antiretroviral therapy (HAART) because of viral resistance-associated mutations.

Objective:To identify virus genotype and the presence of mutations that alter the susceptibility to HAART, and factors associated with the occurrence of these mutations.

Methods:A cross-sectional study was conducted on adults living with HIV attending a specialized outpatient clinic in southern Santa Catarina, Brazil. The participants were interviewed and had blood samples collected for analysis. Those with detectable viral load were genotyped.

Results:Out of the 629 patients recruited, 127 subjects were included due to having a detectable viral load. The most common mutations were M184V and K103N. HIV-1 subtype C was the most prevalent strain. Resistance to HAART was associated with modification in the treatment regimen (p (<0.001).

Conclusion:This study concluded that the circulating subtype virus was subtype C and that the mutations K103N and M184V were the most prevalent strains in southern Santa Catarina, Brazil.

Sobre autores

Chaiana Mendes Marcon

Postgraduate Program in Health Sciences, University of Southern Santa Catarina at Tubarão

Email: info@benthamscience.net

Aline Schlindwein

Postgraduate Program in Health Sciences, University of Southern Santa Catarina at Tubarão

Email: info@benthamscience.net

Luis de Macedo Brigido

Department of Virology, Adolfo Lutz Institute

Email: info@benthamscience.net

Giselle Lopez-Lopes

Department of Virology, Adolfo Lutz Institute

Email: info@benthamscience.net

Gabriela Cabral

Department of Virology, Adolfo Lutz Institute

Email: info@benthamscience.net

Fabiana Schuelter-Trevisol

Postgraduate Program in Health Sciences, University of Southern Santa Catarina at Tubarão

Autor responsável pela correspondência
Email: info@benthamscience.net

Bibliografia

  1. Ministério da Saúde. Brasília: Manual técnico para diagnóstico da infecção pelo HIV. 2016. Available From: http://www.pncq.org.br/uploads/2014/manual_tecnico_hiv_2014_final_pdf_p__31450.pdf
  2. Panda S, Pahari S, Roy S, Mandal A, Kuila S. Adherence to anti-retroviral therapy & factors associated with it: A community based cross-sectional study from West Bengal, India. Indian J Med Res 2015; 142(3): 301-10. doi: 10.4103/0971-5916.166595 PMID: 26458346
  3. Liu J, Yan J, Yang W, Xue X, Sun G, Liu C. Analysis of HIV-1 drug resistance among 1 922 individuals experiencing virological failure of first-line antiretroviral therapy in Henan province. Zhonghua Yu fang Yi XueZa Zhi 2015; 49(11): 950.
  4. Pattery T, Verlinden Y, De Wolf H, et al. Development and performance of conventional HIV-1 phenotyping (Antivirogram®) and genotype-based calculated phenotyping assay (virco®TYPE HIV-1) on protease and reverse transcriptase genes to evaluate drug resistance. Intervirology 2012; 55(2): 138-46. doi: 10.1159/000332013 PMID: 22286884
  5. Van Houtte M, Picchio G, Van Der Borght K, Pattery T, Lecocq P, Bacheler LT. A comparison of HIV-1 drug susceptibility as provided by conventional phenotyping and by a phenotype prediction tool based on viral genotype. J Med Virol 2009; 81(10): 1702-9. doi: 10.1002/jmv.21585 PMID: 19697398
  6. Gräf T, Passaes CPB, Ferreira LGE, et al. HIV-1 genetic diversity and drug resistance among treatment naïve patients from Southern Brazil: An association of HIV-1 subtypes with exposure categories. J Clin Virol 2011; 51(3): 186-91. doi: 10.1016/j.jcv.2011.04.011 PMID: 21622023
  7. Leal E, Martins LO, Janini M, Diaz RS. Evolutionary dynamics of HIV-1 BF and CB recombinants and its parental counterparts in South America. Retrovirology (Auckl) 2008; 1: 1-14. doi: 10.4137/RRT.S1045
  8. Grinberg G, Giron LB, Knoll RK, et al. High prevalence and incidence of HIV-1 in a counseling and testing center in the city of Itajaí, Brazil. Braz J Infect Dis 2015; 19(6): 631-5. doi: 10.1016/j.bjid.2015.08.001 PMID: 26361837
  9. Boyd MA, Moore CL, Molina JM, et al. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: An exploratory analysis. Lancet HIV 2015; 2(2): e42-51. doi: 10.1016/S2352-3018(14)00061-7 PMID: 26424460
  10. Morales L, Rogowski J, Freedman VA, Wickstrom SL, Adams JL, Escarce JJ. Sociodemographic differences in use of preventive services by women enrolled in Medicare+Choice plans. Prev Med 2004; 39(4): 738-45. doi: 10.1016/j.ypmed.2004.02.041 PMID: 15351540
  11. Woods CK, Brumme CJ, Liu TF, et al. Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool. J Clin Microbiol 2012; 50(6): 1936-42. doi: 10.1128/JCM.06689-11 PMID: 22403431
  12. Stanford University. Estados Unidos: HIV Drug resistence database. 2019. Available From: https://hivdb.satanford.edu
  13. Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. MEGA6: Molecular evolutionary genetics analysis version 6.0. Mol Biol Evol 2013; 30(12): 2725-9. doi: 10.1093/molbev/mst197 PMID: 24132122
  14. Saitou N, Nei M. The neighbor-joining method: A new method for reconstructing phylogenetic trees. Mol Biol Evol 1987; 4(4): 406-25. PMID: 3447015
  15. Gräf T, Machado Fritsch H, de Medeiros RM, Maletich Junqueira D, Esteves de Matos Almeida S, Pinto AR. Comprehensive characterization of HIV-1 molecular epidemiology and demographic history in the brazilian region most heavily affected by AIDS. J Virol 2016; 90(18): 8160-8. doi: 10.1128/JVI.00363-16 PMID: 27384663
  16. Felsenstein J. Confidence limits on phylogenies: An approach using the bootstrap. Evolution 1985; 39(4): 783-91. doi: 10.2307/2408678 PMID: 28561359
  17. Schuelter-Trevisol F, Silva MV, Oliveira CM, Rodrigues R. HIV genotyping among female sex workers in the State of Santa Catarina. Rev Soc Bras Med Trop 2007; 40(3): 259-63. doi: 10.1590/S0037-86822007000300001 PMID: 17653456
  18. Soares EAJM, Martínez AMB, Souza TM, et al. HIV-1 subtype C dissemination in southern Brazil. AIDS 2005; 19 (Suppl. 4): S81-6. doi: 10.1097/01.aids.0000191497.00928.e4 PMID: 16249660
  19. Avanzi VM, Vicente BA, Beloto NCP, et al. Profile of HIV subtypes in HIV/HBV- and HIV/HCV-coinfected patients in Southern Brazil. Rev Soc Bras Med Trop 2017; 50(4): 470-7. doi: 10.1590/0037-8682-0450-2016 PMID: 28954067
  20. Corado ALG, Bello G, Leão RAC, Granja F, Naveca FG. HIV-1 genetic diversity and antiretroviral drug resistance among individuals from Roraima state, northern Brazil. PLoS One 2017; 12(3): e0173894. doi: 10.1371/journal.pone.0173894 PMID: 28301548
  21. Brindeiro RM, Diaz RS, Sabino EC, et al. Brazilian Network for HIV Drug Resistance Surveillance (HIV-BResNet): A survey of chronically infected individuals. AIDS 2003; 17(7): 1063-9. doi: 10.1097/00002030-200305020-00016 PMID: 12700457
  22. Osmanov S, Pattou C, Walker N, Schwardländer B, Esparza J. Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000. J Acquir Immune Defic Syndr 2002; 29(2): 184-90. doi: 10.1097/00042560-200202010-00013 PMID: 11832690
  23. Wainberg MA, Zaharatos GJ, Brenner BG. Development of antiretroviral drug resistance. N Engl J Med 2011; 365(7): 637-46. doi: 10.1056/NEJMra1004180 PMID: 21848464
  24. Kiwelu IE, Novitsky V, Margolin L, et al. Frequent intra-subtype recombination among HIV-1 circulating in Tanzania. PLoS One 2013; 8(8): e71131. doi: 10.1371/journal.pone.0071131 PMID: 23940702
  25. Wainberg MA, Moisi D, Oliveira M, Toni TD, Brenner BG. Transmission dynamics of the M184V drug resistance mutation in primary HIV infection. J Antimicrob Chemother 2011; 66(10): 2346-9. doi: 10.1093/jac/dkr291 PMID: 21750100
  26. Melikian GL, Rhee SY, Varghese V, et al. Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: Implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing. J Antimicrob Chemother 2014; 69(1): 12-20. doi: 10.1093/jac/dkt316 PMID: 23934770
  27. Hamers RL, Sigaloff KCE, Wensing AM, et al. Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: Implications for second-line ART strategies. Clin Infect Dis 2012; 54(11): 1660-9. doi: 10.1093/cid/cis254 PMID: 22474222
  28. Hill A, McBride A, Sawyer AW, Clumeck N, Gupta RK. Resistance at virological failure using boosted protease inhibitors versus nonnucleoside reverse transcriptase inhibitors as first-line antiretroviral therapy-implications for sustained efficacy of ART in resource-limited settings. J Infect Dis 2013; 207 (Suppl. 2): S78-84. doi: 10.1093/infdis/jit112 PMID: 23687293
  29. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308(4): 387-402. doi: 10.1001/jama.2012.7961 PMID: 22820792
  30. Taiwo B. Understanding transmitted HIV resistance through the experience in the USA. Int J Infect Dis 2009; 13(5): 552-9. doi: 10.1016/j.ijid.2008.10.008 PMID: 19136289
  31. Götte M, Arion D, Parniak MA, Wainberg MA. The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis. J Virol 2000; 74(8): 3579-85. doi: 10.1128/JVI.74.8.3579-3585.2000 PMID: 10729133
  32. Rhee SY, Taylor J, Fessel WJ, et al. HIV-1 protease mutations and protease inhibitor cross-resistance. Antimicrob Agents Chemother 2010; 54(10): 4253-61. doi: 10.1128/AAC.00574-10 PMID: 20660676
  33. Sterrantino G, Zaccarelli M, Colao G, et al. Genotypic resistance profiles associated with virological failure to darunavir-containing regimens: A cross-sectional analysis. Infection 2012; 40(3): 311-8. doi: 10.1007/s15010-011-0237-y PMID: 22237471
  34. De Meyer S, Lathouwers E, Dierynck I, De Paepe E, Van Baelen B, Vangeneugden T. Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients. AIDS 2009; 23(14): 1829-40.
  35. Lambert-Niclot S, Masquelier B, Cohen Codar I, et al. Impact of lopinavir/ritonavir use on antiretroviral resistance in recent clinical practice. J Antimicrob Chemother 2012; 67(10): 2487-93. doi: 10.1093/jac/dks226 PMID: 22733652
  36. Santos JR, Llibre JM, Imaz A, et al. Mutations in the protease gene associated with virological failure to lopinavir/ritonavir-containing regimens. J Antimicrob Chemother 2012; 67(6): 1462-9. doi: 10.1093/jac/dks080 PMID: 22431669
  37. Stekler JD, Milne R, Payant R, et al. Transmission of HIV-1 drug resistance mutations within partner-pairs: A cross-sectional study of a primary HIV infection cohort. PLoS Med 2018; 15(3): e1002537. doi: 10.1371/journal.pmed.1002537 PMID: 29584723
  38. Lopes CAF, Soares MA, Falci DR, Sprinz E. The evolving genotypic profile of HIV-1 mutations related to antiretroviral treatment in the North Region of Brazil. BioMed Res Int 2015; 2015: 1-6. doi: 10.1155/2015/738528 PMID: 26543866
  39. Buckton AJ, Prabhu D, Motamed C, et al. Increased detection of the HIV-1 reverse transcriptase M184V mutation using mutation-specific minority assays in a UK surveillance study suggests evidence of unrecognized transmitted drug resistance. HIV Med 2011; 12(4): 250-4. doi: 10.1111/j.1468-1293.2010.00882.x PMID: 21371237
  40. Rusconi S, De Pasquale MP, Milazzo L, et al. Loss of lamivudine resistance in a zidovudine and lamivudine dual-resistant HIV-1 isolate after discontinuation of in vitro lamivudine drug pressure. Antivir Ther 1998; 3(4): 203-7. doi: 10.1177/135965359800300407 PMID: 10682139
  41. Metzner KJ, Bonhoeffer S, Fischer M, et al. Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. J Infect Dis 2003; 188(10): 1433-43. doi: 10.1086/379215 PMID: 14624368
  42. Karade SK, Kulkarni SS, Ghate MV, et al. Antiretroviral resistance following immunological monitoring in a resource-limited setting of western India: A cross-sectional study. PLoS One 2017; 12(8): e0181889. doi: 10.1371/journal.pone.0181889 PMID: 28763465
  43. Farrokhi M, Moallemi S, Shirkoohi R, et al. Antiretroviral drug resistance mutations among HIV treatment failure patients in Tehran, Iran. Iran J Public Health 2017; 46(9): 1256-64. PMID: 29026792
  44. Ananworanich J, Sirivichayakul S, Pinyakorn S, et al. High prevalence of transmitted drug resistance in acute HIV-infected Thai men who have sex with men. J Acquir Immune Defic Syndr 2015; 68(4): 481-5. doi: 10.1097/QAI.0000000000000502 PMID: 25559593
  45. Dai L, Li N, Wei F, et al. Transmitted antiretroviral drug resistance in the men who have sex with men HIV patient cohort, Beijing, China, 2008-2011. Viral Immunol 2014; 27(8): 392-7. doi: 10.1089/vim.2014.0025 PMID: 25084305
  46. Breda A, Fernandes CL, de Matos Almeida SE, et al. Bioinformatics tools for HIV-1 identification in Southern Brazilian States. Lect Notes Comput Sci 2005; 3594: 234-7. doi: 10.1007/11532323_31
  47. Soares EAJM, Santos RP, Pellegrini JA, Sprinz E, Tanuri A, Soares MA. Epidemiologic and molecular characterization of human immunodeficiency virus type 1 in southern Brazil. J Acquir Immune Defic Syndr 2003; 34(5): 520-6. doi: 10.1097/00126334-200312150-00012 PMID: 14657764
  48. Soares MA, de Oliveira T, Brindeiro RM, et al. A specific subtype C of human immunodeficiency virus type 1 circulates in Brazil. AIDS 2003; 17(1): 11-21. doi: 10.1097/00002030-200301030-00004 PMID: 12478065

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bentham Science Publishers, 2024